EP4079281A1 - Anti-inflammatory liquid composition for covering oral mucosa, and medicinal composition for prevention and/or treatment of stomatitis using same - Google Patents
Anti-inflammatory liquid composition for covering oral mucosa, and medicinal composition for prevention and/or treatment of stomatitis using same Download PDFInfo
- Publication number
- EP4079281A1 EP4079281A1 EP20902159.1A EP20902159A EP4079281A1 EP 4079281 A1 EP4079281 A1 EP 4079281A1 EP 20902159 A EP20902159 A EP 20902159A EP 4079281 A1 EP4079281 A1 EP 4079281A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- rosin
- oral mucosa
- liquid composition
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 123
- 239000007788 liquid Substances 0.000 title claims abstract description 42
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 36
- 210000002200 mouth mucosa Anatomy 0.000 title claims abstract description 31
- 208000003265 stomatitis Diseases 0.000 title claims description 11
- 230000002265 prevention Effects 0.000 title description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims abstract description 100
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims abstract description 100
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims abstract description 100
- 229920001800 Shellac Polymers 0.000 claims abstract description 35
- 239000004208 shellac Substances 0.000 claims abstract description 35
- 229940113147 shellac Drugs 0.000 claims abstract description 35
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims abstract description 35
- 235000013874 shellac Nutrition 0.000 claims abstract description 35
- 239000004859 Copal Substances 0.000 claims abstract description 25
- 241000782205 Guibourtia conjugata Species 0.000 claims abstract description 23
- 239000002904 solvent Substances 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 97
- 239000004615 ingredient Substances 0.000 claims description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims description 2
- 240000000912 Macadamia tetraphylla Species 0.000 claims description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 241000411851 herbal medicine Species 0.000 claims description 2
- -1 jojoba oil Substances 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- 239000010466 nut oil Substances 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000010497 wheat germ oil Substances 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 abstract description 33
- 210000004400 mucous membrane Anatomy 0.000 abstract description 20
- 230000007794 irritation Effects 0.000 abstract description 18
- 238000001035 drying Methods 0.000 abstract description 17
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 230000000052 comparative effect Effects 0.000 description 63
- 239000010408 film Substances 0.000 description 56
- 239000000243 solution Substances 0.000 description 53
- 239000011347 resin Substances 0.000 description 19
- 229920005989 resin Polymers 0.000 description 19
- 239000000463 material Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000002075 main ingredient Substances 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000002324 mouth wash Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229940112822 chewing gum Drugs 0.000 description 5
- 235000015218 chewing gum Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229960002117 triamcinolone acetonide Drugs 0.000 description 5
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920002689 polyvinyl acetate Polymers 0.000 description 4
- 239000011118 polyvinyl acetate Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940034610 toothpaste Drugs 0.000 description 4
- 239000000606 toothpaste Substances 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 3
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229940051866 mouthwash Drugs 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000016649 Copaifera officinalis Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229940042125 oral ointment Drugs 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000011297 pine tar Substances 0.000 description 1
- 229940068124 pine tar Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L93/00—Compositions of natural resins; Compositions of derivatives thereof
- C08L93/02—Shellac
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L93/00—Compositions of natural resins; Compositions of derivatives thereof
- C08L93/04—Rosin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Definitions
- the present invention relates to a liquid composition for covering oral mucosa, which has an anti-inflammatory effect and an antibacterial effect, and suppresses or heals increased wound and inflammation in the oral cavity by applying the composition to the oral mucosa to form a film, as well as a pharmaceutical composition for prevention and/or treatment of stomatitis using the same.
- a liquid plaster, a liquid bandage, or the like has been proposed as a skin protectant for protecting a skin by forming a film on the skin in order to protect a wound and prevent irritation.
- Nitrocellulose, octyl cyanoacrylate, or the like is used as a film-forming agent for a liquid plaster, and ethyl acetate, ethyl ether, or the like is used as a solvent.
- Ethyl acetate and ethyl ether are toxic to the human body, and therefore it is not preferable to use such a liquid plaster in the oral cavity.
- the film-forming agent itself does not have an anti-inflammatory effect, and a medicinal ingredient having an anti-inflammatory effect is added.
- a therapeutic patch for stomatitis As a therapeutic agent for inflammation in the oral cavity, a therapeutic patch for stomatitis has been proposed [Aftach (registered trademark), manufactured by TEIJIN PHARMA LIMITED. Sato Pharmaceutical Co., Ltd.: (see " Therapeutic Agent for Stomatitis/Aftach", New Drugs 2007 edition, published by Yakuji Nippo, Limited, pp. 285-286 )].
- a medicinal ingredient such as triamcinolone acetonide is mixed with a hydrophilic resin such as a carboxyvinyl polymer, and the mixture is formed into a patch, and the patch is applied to an affected area in order to aim at attaining a sustained release effect of the agent.
- an oral retention type base which forms an adhesive film by saliva when applied to the oral cavity and reliably remains in an affected area for a long time without being flowed by saliva
- an invention related to an oral retention type base capable of forming an adhesive film, which is formed in a liquid or paste form by dissolving a film-forming polymeric substance soluble in a lower alcohol and insoluble or poorly soluble in water (such as ethyl cellulose or polyvinyl acetate) and a tackifier resin (such as a rosin resin or a shellac resin) in an alcohol solvent (see JP S62-142112 A ).
- the therapeutic patch for stomatitis (Aftach) used in the oral cavity contains triamcinolone acetonide as a main ingredient, and is a circular solid with a diameter of about 7 mm and a thickness of 1.1 mm.
- the patch of this circular solid is applied to the affected area, the patch is pressed with a finger to allow the patch to be attached to the area.
- the patch is immediately removed when touched with a tongue because the patch is thick.
- the touch on the tongue is poor and causes a considerable discomfort, and there is a disadvantage that, for example, the patch is peeled off immediately after eating food or drinking water, which is not suitable for children.
- hospitalized patients, elderly persons, and the like there is a high possibility that the patch is accidentally swallowed, and there is a possibility that the patch adheres to the esophageal mucosa to cause serious complications.
- the above-described ointment agent for treating stomatitis (Ortexer) used in the oral cavity contains triamcinolone acetonide as a main ingredient, and a finger or a cotton swab is used to apply this ointment to an affected area, but it is difficult to allow the ointment to adhere to the area.
- the agent is not particularly suitable for children.
- the attached ointment evokes a sticky and rough feeling and an uncomfortable feeling, and also a feeling of discomfort in taste.
- the duration time is also short.
- a rosin, a processed rosin, or the like as an inhibitor against oral bacteria involved in the development of periodontal disease or gingivitis is added to an oral composition such as a chewing gum, a candy, a toothpaste, or a mouth rinse.
- an oral composition such as a chewing gum, a candy, a toothpaste, or a mouth rinse.
- the addition amount thereof is as very small as 0.001 to 1 wt%.
- the main ingredients of the chewing gum described in JP H04-66523 A are a gum base and saccharides, and the chewing gum remains in the oral cavity for a long time, but does not have an adherence property enough for the chewing gum to adhere to the mucous membrane in the oral cavity.
- the addition amount of the rosin and the processed rosin is very small, and thus the rosin and the processed rosin are hardly involved in the adherence property of the product.
- the main ingredients of the candy described in JP H04-66523 A are granulated sugar and starch syrup, and thus materials that do not adhere to the teeth or mucous membrane in the oral cavity are selected.
- the addition amount of the rosin and the processed rosin is very small, and thus the rosin and the processed rosin are hardly involved in the adherence property of the product.
- the main ingredients of the toothpaste described in JP H04-66523 A are polishing agents such as dibasic calcium phosphate and glycerin, and materials that do not adhere to the teeth or mucous membrane in the oral cavity are selected as materials of the product.
- the mouth rinse described in JP H04-66523 A contains water and an ethanol solution as main ingredients, and only trace amounts of the rosin and the processed rosin are added thereto. Therefore, although this mouth rinse is a liquid composition, it does not have the ability to form a film on the mucous membrane in the oral cavity.
- JP 2009-514789 A there is used a composition containing a tree resin or an extract thereof or a derivative thereof as an antimicrobial agent against bacteria involved in caries, gingivitis, and other periodontal diseases.
- a tree resin a rosin or a colophonium is used.
- this antimicrobial agent is added to a chewing gum, a dentifrice, or a mouthwash in a very small amount.
- the amount of the agent to be added is limited to a range of 1 to 10,000 ppm (i.e., a range of 0.0001 to 1%) in the claims.
- the amount of the agent to be added to the mouth rinse is in a range of 0.01 to 0.001%, and the amount of the agent to be added to the toothpaste is in a range of 0.1 to 0.001%, and each of the amounts is very small.
- the mouthwash as a product of the Examples is prepared by adding large amounts of ethanol and water to a 0.1% aqueous alkali solution of rosin acid, the mouthwash has no ability to adhere to the mucous membrane in the oral cavity to form a film.
- the toothpaste is also produced by adding polishing agents such as silica and titanium dioxide, and thickeners such as glycerin and xanthan gum.
- the amount of the rosin is as small as 0.001%, and the rosin does not function at all as an adhesive material or a film-forming material.
- the materials are selected so that the dentifrice product itself does not adhere to the mucous membrane in the oral cavity.
- the retention type base capable of forming an oral film described in JP S62-142112 A has a problem in terms of quick-drying property. It is presumed that this is because the content of the film-forming polymeric substance such as ethyl cellulose or polyvinyl acetate is relatively large.
- An object of the present invention is to provide an anti-inflammatory liquid composition for covering oral mucosa, which is different from the conventional oral care products as described above, adheres to a mucous membrane in the oral cavity to form a film excellent in quick-drying property and durability, covers, for example, an affected area where a wound or inflammation is developed to protect from external irritation, and prevents or heals increased wound and inflammation.
- the present inventors have carried out a diligent study to solve the problem described above. As a result, the present inventors have found that the above problem can be solved by using, as an anti-inflammatory liquid composition for covering oral mucosa, a composition containing a rosin and a shellac (and in some cases, a copal) in a predetermined content in a solvent, and have completed the present invention.
- the anti-inflammatory liquid composition for covering oral mucosa contains a rosin, a shellac, and a solvent.
- the composition is characterized in that the content of the rosin is 1 wt% or more and 15 wt% or less relative to the total amount of the composition, the content of the shellac is 35 wt% or more and 45 wt% or less relative to the total amount of the composition, and the total content of the rosin, the shellac, and the copal is 45 wt% or more and 55 wt% or less relative to the total amount of the composition.
- an anti-inflammatory liquid composition for covering oral mucosa which is different from conventional oral care products, and with which the above-described problem can be solved.
- One aspect of the present invention is an anti-inflammatory liquid composition for covering oral mucosa including: a rosin; a shellac; and a solvent in which a content of the rosin is 1 wt% or more and 15 wt% or less relative to a total amount of the composition, and a content of the shellac is 35 wt% or more and 45 wt% or less relative to the total amount of the composition, and a total content of the rosin, the shellac, and a copal is 45 wt% or more and 55 wt% or less relative to the total amount of the composition.
- the rosin has antibacterial and anti-inflammatory effects against cariogenic bacteria and periodontopathic bacteria, as described in the documents in the related art.
- the wound site or inflamed site is covered with a rosin-containing film in order to protect the inflammation, wound, or the like in the oral cavity from external irritation and at the same time to maintain antibacterial and anti-inflammatory effects.
- the anti-inflammatory effect of the rosin is exhibited when the content of the rosin is more than 0.1 wt%.
- the lower limit value of the content of the rosin is set to 1 wt% in consideration of gradual dissolution and permeation, on the assumption that the above-mentioned effect is exhibited when the content of the rosin is 10 times that of the composition.
- rosin is a resin ingredient obtained from pine tar
- an ethanol solution of rosin has a film-forming property.
- the durability of the film is short.
- irritation to the mucous membrane is strong, there is a stiff feeling due to the film in the oral cavity, and there is discomfort at the time of use.
- rosin is commercially available as solid gum rosin. When the rosin is used in the composition for covering oral mucosa, it is necessary that the rosin is dissolved in a solvent such as ethanol and used.
- the rosin in order to produce an ethanol solution of rosin, the rosin is put into ethanol and dissolved under stirring. Although it is sufficient to stir the rosin solution for several minutes when the concentration of the rosin solution is several wt%, it may take several hours to stir the solution when the concentration increases. In addition, since the rosin is irritating, when the amount of rosin is increased, the affected area may be stimulated to cause pain, and therefore it is not preferable to excessively increase the concentration of the rosin.
- the shellac as a vehicle (base material) for film formation has better performance than the rosin, it is considered that the shellac is further added in addition to the rosin, resulting in more preferable blending of the base material.
- shellac is commercially available as a 20 to 50% ethanol solution. Therefore, the addition of ethanol to the commercially available solution enables a shellac solution having a concentration lower than the commercially available solution to be easily obtained.
- preparation can be performed by evaporating the ethanol portion in a warm bath at around 40°C or by adding dry powder shellac to the commercially available solution.
- the anti-inflammatory liquid composition for covering oral mucosa which has been completed based on the above findings is characterized in that the composition contains resin ingredients: a rosin and a shellac, and solvents thereof as main ingredients. Ethanol is preferably used as the solvent.
- the content of the rosin as the resin ingredient described above is 1 wt% or more and 15 wt% or less, and preferably 1 wt% or more and 10 wt% or less relative to the total amount of the composition.
- the content of the shellac as the resin ingredient is 35 wt% or more and 45 wt% or less, and preferably 35 wt% or more and 40 wt% or less relative to the total amount of the composition.
- the total content of the rosin, the shellac, and a copal is 45 wt% or more and 55 wt% or less, and the total content is preferably 47 wt% or more and 51 wt% or less relative to the total amount of the composition.
- the composition according to the present invention does not necessarily contain the copal, but when the composition does not contain the copal, the total content of the rosin and the shellac satisfies the above definition.
- a solvent such as ethanol evaporates and a resin film is formed.
- the content of the solvent in the anti-inflammatory liquid composition for covering oral mucosa according to the present invention is 55 wt% or less, and preferably 53 wt% or less.
- the lower limit of the content of the solvent is preferably 40 wt% or more, more preferably 44 wt% or more, and particularly preferably 49 wt% or more.
- the content of ethanol in the composition is preferably 53 wt% or less.
- the lower limit of the content of ethanol is preferably 40 wt% or more, more preferably 44 wt% or more, and particularly preferably 49 wt% or more.
- the content of the solvent (e.g., ethanol) is preferably in a range of 49 to 53 wt%.
- the contents of ethyl cellulose, polyvinyl acetate, and cellulose nitrate are preferably less than 0.5 wt%. More preferably, the contents of film-forming polymeric substances including ethyl cellulose, polyvinyl acetate, and cellulose nitrate (excluding the rosin, the shellac, and the copal) are less than 0.5 wt%. This is because when the contents of the ingredients described above are 0.5 wt% or more, the quick-drying property of the film formed in the oral cavity may be deteriorated.
- the content of each of the ingredients described above is preferably 0.45 wt% or less, more preferably 0.3 wt% or less, still more preferably 0.2 wt% or less, particularly preferably 0.1 wt% or less, and most preferably 0 wt% (free).
- film-forming polymeric substance means a polymer capable of forming a thin film on the surface of an object in a drying step.
- the anti-inflammatory liquid composition for covering oral mucosa according to the present invention further contains a copal as a resin ingredient.
- the surface of the film may be rough due to the blending of the rosin, but there is an advantage that the surface of the film formed can be made smoother by further containing the copal, and the stiffness can be reduced.
- the content of the copal is not particularly limited. Since the copal has a unique resin odor, when the blending amount of the copal is too large, the stiffness may be conversely increased. Thus, the content of the copal is preferably more than 0 wt% and 10 wt% or less, and more preferably 0.1 wt% or more and 8 wt% or less relative to the total amount of the composition.
- the anti-inflammatory liquid composition for covering oral mucosa according to the present invention may further contain an accessory ingredient as long as the effect of the present invention is not adversely affected.
- the accessory ingredient include a medicinal ingredient and a moisturizing ingredient.
- the contents of these accessory ingredients are preferably 1 wt% or less relative to the total amount of the composition.
- Examples of the medicinal ingredient that can be contained as an accessory ingredient include one or two or more selected from the group consisting of, for example, anti-inflammatory agents such as azulene sulfonate sodium and glycyrrhizic acid; antihistamines such as diphenhydramine hydrochloride and chlorpheniramine maleate; anti-inflammatory analgesics such as triamcinolone acetonide and dexamethasone acetate; antibiotics such as cefaclor, amoxicillin, erythromycin, and kanamycin; vitamin preparations such as vitamin B1 and vitamin E; and herbal medicines or Kampo preparations such as Angelica root, cinnamon bark, turmeric, and licorice.
- anti-inflammatory agents such as azulene sulfonate sodium and glycyrrhizic acid
- antihistamines such as diphenhydramine hydrochloride and chlorpheniramine maleate
- anti-inflammatory analgesics such as triamcinolone ace
- the anti-inflammatory liquid composition for covering oral mucosa contains resin ingredients: a rosin and a shellac and solvents thereof as main ingredients.
- a rosin and a shellac and solvents thereof as main ingredients.
- a film can be formed to cover the inflamed site within about 20 seconds. Accordingly, it is possible to prevent external irritation. As a result, the pain of the affected area can be alleviated and the patient's burden can be reduced.
- the rosin contained in the composition according to the present invention contains an anti-inflammatory ingredient, it is possible to prevent the expansion of the inflamed site.
- the film of the composition according to the present invention covers and protects the affected area, healing of the inflamed site can be promoted.
- the rosin suppresses T cell mitogen (concanavalin A)-responsive proliferation of human peripheral-blood mononuclear cells (PBMCs), and inhibits production of five cytokines (proteins secreted from cells of the immune system: IL-6, IL-10, TNF- ⁇ , IFN- ⁇ , and IL-17) from PBMCs in a concentration-dependent manner.
- T cell mitogen concanavalin A
- cytokines proteins secreted from cells of the immune system: IL-6, IL-10, TNF- ⁇ , IFN- ⁇ , and IL-17
- the composition according to the present invention contains an ingredient used as a food additive as a main ingredient, the composition is safe to be swallowed.
- the film dissolves naturally and does not adhere to the mucous membrane of esophagus or the like, so there is no possibility of complication occurrence, or the like.
- the content of the rosin as the resin ingredient described above is 1 wt% or more relative to the total amount of the composition. This is in consideration of the fact that although the antimicrobial effect of the rosin is recognized from 0.1 wt%, the rosin is gradually dissolved and permeated to exert its effect.
- the upper limit of the content of the rosin is 15 wt% or less relative to the total amount of the composition. When the content of the rosin is more than 15 wt%, the surface of the formed film becomes stiff and the touch on the tongue is deteriorated, or cracking occurs and the film is easily peeled off. This is problematic.
- composition according to the present invention by dissolving the rosin in an ethanol solution (usually, a solution having a concentration of 50%) of shellac, when the content of the rosin exceeds 15 wt%, it takes one day or more to dissolve the rosin, leading to deterioration of productivity. This is problematic.
- the total content of the rosin and the shellac (and further a copal in the case of containing the copal) as resin ingredients is 45 wt% or more and 55 wt% or less relative to the total amount of the composition.
- the total content is less than 45 wt%, there is a problem that the adhesion of the formed film to the mucous membrane and the durability are deteriorated and the film is easily peeled off.
- the irritation to the mucous membrane may be enhanced.
- the composition according to the present invention is dried in about 10 to 20 seconds, but this degree is the practical limit.
- the drying time becomes long, and when the total content is, for example, 60 wt%, it takes several minutes to dry the composition.
- the content of the rosin in the composition according to the present invention is 1 wt% or more and 15 wt% or less relative to the total amount of the composition.
- the content of the shellac in the composition according to the present invention was set to a range of 35 wt% or more and 45 wt% or less relative to the total amount of the composition.
- the feeling of the surface of the film is made smooth, and it is possible to form a film having elasticity and high durability.
- the film formed by applying the composition according to the present invention is practically tasteless, and even when a tongue or the like touches the film, the film cannot be easily taken off, and there is no need to refrain from drinking or eating after application.
- the total content of the rosin, the shellac, and the copal is 45 wt% or more and 55 wt% or less.
- the content of ethanol or the like as a solvent is 55 wt% or less, and the irritation can be reduced.
- the film formed by the composition containing the rosin, the shellac, and the copal is not easily peeled off even when the film comes into contact with water because the film is hardly soluble in water, and there is an advantage that the film has durability for several hours even when the film is applied to a portion with significant movement in the oral cavity.
- the film is applied to gums or the like with little movement, it is possible to form a film having durability for 6 hours or more.
- the composition according to the present invention not only has an effect of protecting stomatitis by coating the stomatitis to suppress inflammation, but also has an effect of suppressing proliferation of oral bacteria such as cariogenic bacteria and periodontopathic bacteria by the antibacterial activity of the rosin gradually dissolved in saliva because the film remains in the oral cavity for a long time.
- the composition is also available as a sustained oral dosage form or a new dosage form of transdermal absorption.
- a pharmaceutical composition for preventing and/or treating stomatitis including the anti-inflammatory liquid composition for covering oral mucosa according to the present invention.
- Liquid compositions of Examples and Comparative Examples were prepared by the following method.
- the blending amounts of raw materials in each of the Examples and each of the Comparative Examples are shown in Table 1 below.
- the blending amounts of components in each of the Examples and each of the Comparative Examples are shown in Table 2 below.
- the Examples and Comparative Examples shown in Tables 1 and 2 are arranged in ascending order of resin concentration.
- Table 1 Formulation of raw material of anti-inflammatory liquid composition for covering oral mucosa Sample Nos. Formulation ratios of raw materials (wt%) Gum rosin Laccoat *1 Copal solution *2 Ethanol *3 Total Example 1 10.0 80.0 3.3 6.7 100.0 Example 2 8.0 80.0 6.7 5.3 100.0 Example 3 6.0 80.0 13.3 0.7 100.0 Example 4 10.0 80.0 0.0 10.0 100.0 Example 5 10.0 70.0 16.7 3.3 100.0 Example 6 10.0 76.0 3.3 10.7 100.0 Example 7 1.0 80.0 15.0 *4 4.0 100.0 Example 8 3.0 80.0 10.0 *4 7.0 100.0 Example 9 6.0 80.0 2.5 *4 11.5 100.0 Comparative Example 1 33.3 66.7 0.0 0.0 100.0 Comparative Example 2 30.0 60.0 0.0 10.0 100.0 Comparative Example 3 10.0 71.4 *5 0.0 18.6 100.0 Comparative Example 4 33.3 0.
- Table 2 Formulation of raw material of anti-inflammatory liquid composition for covering oral mucosa Sample Nos. Formulation ratios of raw materials (wt%) Rosin Shellac Copal Ethanol Total Example 1 10.0 40.0 1.0 49.0 100.0 Example 2 8.0 40.0 2.0 50.0 100.0 Example 3 6.0 40.0 4.0 50.0 100.0 Example 4 10.0 40.0 0.0 50.0 100.0 Example 5 10.0 35.0 5.0 50.0 100.0 Example 6 10.0 38.0 1.0 51.0 100.0 Example 7 1.0 40.0 6.0 53.0 100.0 Example 8 3.0 40.0 4.0 53.0 100.0 Example 9 6.0 40.0 1.0 53.0 100.0 Comparative Example 1 33.3 33.3 0.0 33.4 100.0 Comparative Example 2 30.0 30.0 0.0 40.0 100.0 Comparative Example 3 10.0 50.0 0.0 40.0 100.0 Comparative Example 4 33.3 0.0 20.0 46.7 100.0 Comparative Example 5 25.0 25.0 0.0 50.0 100.0 Comparative Example 6 10.0 25.0 12.0 53.0 100.0 Comparative Example 7 17.0 40.0 0.0 43
- the liquid composition was applied to 5 subjects after wiping off saliva at the inner edge of the lower lip, i.e., a mucous membrane in the oral cavity, followed by drying until a film was formed. Thereafter, the feeling at the lower portion of the surface of the film or the feeling in the oral cavity, i.e., tensive feeling or stiff feeling on the surface of the film, was evaluated according to the following three grades: 0 to 2, and the results of 5 subjects were averaged. When the average value was less than 1.5, it was determined that there was no practical problem. The results are shown in Table 3 below: Stiffness:
- the liquid composition was applied to 5 subjects after wiping off saliva at the inner edge of the lower lip, i.e., a mucous membrane in the oral cavity. After 10 seconds, the degree of dryness of the film was checked with a fingertip. After 20 seconds, the degree of dryness was checked again with a fingertip and evaluated according to the following three grades: 0 to 2, and the results of 5 people were averaged. When the average value was less than 1.5, it was determined that there was no practical problem. The results are shown in Table 3 below: Quick-drying property:
- the liquid composition was applied to the inner edge of the lower lip and the outside of the upper gum of each of the 5 subjects. Next, it was confirmed whether or not the covering material remained every hour. At this time, checking was carried out in 1 hour, the subjects drank water or gargled lightly. In addition, checking was carried out in 2 hours, and then the subjects had meals. Furthermore, checking was carried out in 3 hours, and then the subjects were allowed to freely drink water and have meals.
- the time when the whole covering material was peeled off was recorded.
- the film was peeled off at the time of checking 1 hour later it was recorded as 1 hour
- the film was remained at the time of checking 2 hours later but peeled off at the time of checking 3 hours later, it was recorded as 3 hours
- the film was peeled off at the time of checking 7 hours later it was recorded as 7 hours
- the film was not peeled at that time it was uniformly recorded as 8 hours.
- the results of 5 subjects were averaged. Then, for the inner edge of the lower lip, it was determined that there was no practical problem if the average value was 2.0 hours or more.
- the addition of the shellac improved the feeling, quick-drying property, and durability of the film. This is apparent from the fact that Comparative Examples 4 and 12 without addition of the shellac were inferior in all respects of feeling, quick-drying property, and durability.
Abstract
Description
- The present invention relates to a liquid composition for covering oral mucosa, which has an anti-inflammatory effect and an antibacterial effect, and suppresses or heals increased wound and inflammation in the oral cavity by applying the composition to the oral mucosa to form a film, as well as a pharmaceutical composition for prevention and/or treatment of stomatitis using the same.
- Conventionally, a liquid plaster, a liquid bandage, or the like has been proposed as a skin protectant for protecting a skin by forming a film on the skin in order to protect a wound and prevent irritation. Nitrocellulose, octyl cyanoacrylate, or the like is used as a film-forming agent for a liquid plaster, and ethyl acetate, ethyl ether, or the like is used as a solvent. Ethyl acetate and ethyl ether are toxic to the human body, and therefore it is not preferable to use such a liquid plaster in the oral cavity. In addition, although it is possible to protect external irritation by the film, the film-forming agent itself does not have an anti-inflammatory effect, and a medicinal ingredient having an anti-inflammatory effect is added.
- Recently, as a therapeutic agent for inflammation in the oral cavity, a therapeutic patch for stomatitis has been proposed [Aftach (registered trademark), manufactured by TEIJIN PHARMA LIMITED. Sato Pharmaceutical Co., Ltd.: (see "Therapeutic Agent for Stomatitis/Aftach", New Drugs 2007 edition, published by Yakuji Nippo, Limited, pp. 285-286)]. In this oral therapeutic agent, a medicinal ingredient such as triamcinolone acetonide is mixed with a hydrophilic resin such as a carboxyvinyl polymer, and the mixture is formed into a patch, and the patch is applied to an affected area in order to aim at attaining a sustained release effect of the agent.
- There has also been proposed an ointment agent for treating stomatitis which is in the form of an ointment and is applied to an affected area in the oral cavity [Ortexer (registered trademark) Oral Ointment 0.1%, manufactured by BEE BRAND MEDICO DENTAL. CO. LTD., sold by NIHON GENERIC Co., Ltd.: (see "Ortexer (registered trademark) Oral Ointment 0.1%" package insert, revised in December 2017 (2nd edition))]. This ointment is obtained by adding triamcinolone acetonide, which is an anti-inflammatory steroid drug, to a gelling base.
- Furthermore, oral care compositions focusing on the antibacterial activity of rosin have also been proposed (see
JP H04-66523 A JP 2009-514789 A JP S62-142112 A - The therapeutic patch for stomatitis (Aftach) used in the oral cavity contains triamcinolone acetonide as a main ingredient, and is a circular solid with a diameter of about 7 mm and a thickness of 1.1 mm. When the patch of this circular solid is applied to the affected area, the patch is pressed with a finger to allow the patch to be attached to the area. Not only the attached patch causes pain and suffering, but also the patch is immediately removed when touched with a tongue because the patch is thick. In addition, the touch on the tongue is poor and causes a considerable discomfort, and there is a disadvantage that, for example, the patch is peeled off immediately after eating food or drinking water, which is not suitable for children. In hospitalized patients, elderly persons, and the like, there is a high possibility that the patch is accidentally swallowed, and there is a possibility that the patch adheres to the esophageal mucosa to cause serious complications.
- In addition, the above-described ointment agent for treating stomatitis (Ortexer) used in the oral cavity contains triamcinolone acetonide as a main ingredient, and a finger or a cotton swab is used to apply this ointment to an affected area, but it is difficult to allow the ointment to adhere to the area. Thus, the agent is not particularly suitable for children. Furthermore, the attached ointment evokes a sticky and rough feeling and an uncomfortable feeling, and also a feeling of discomfort in taste. Furthermore, since the ointment is removed when a tongue or the like touches it, the duration time is also short. In addition, there is a disadvantage that it is necessary to avoid food and drink for a while after the application of the ointment.
- In the periodontal pathogen growth inhibitor described in
JP H04-66523 A JP H04-66523 A JP H04-66523 A JP H04-66523 A JP H04-66523 A - In the oral care composition described in
JP 2009-514789 A - Furthermore, according to the study of the present inventors, it has been found that the retention type base capable of forming an oral film described in
JP S62-142112 A - An object of the present invention is to provide an anti-inflammatory liquid composition for covering oral mucosa, which is different from the conventional oral care products as described above, adheres to a mucous membrane in the oral cavity to form a film excellent in quick-drying property and durability, covers, for example, an affected area where a wound or inflammation is developed to protect from external irritation, and prevents or heals increased wound and inflammation. Solution to Problem
- The present inventors have carried out a diligent study to solve the problem described above. As a result, the present inventors have found that the above problem can be solved by using, as an anti-inflammatory liquid composition for covering oral mucosa, a composition containing a rosin and a shellac (and in some cases, a copal) in a predetermined content in a solvent, and have completed the present invention.
- That is, the anti-inflammatory liquid composition for covering oral mucosa according to one aspect of the present invention contains a rosin, a shellac, and a solvent. The composition is characterized in that the content of the rosin is 1 wt% or more and 15 wt% or less relative to the total amount of the composition, the content of the shellac is 35 wt% or more and 45 wt% or less relative to the total amount of the composition, and the total content of the rosin, the shellac, and the copal is 45 wt% or more and 55 wt% or less relative to the total amount of the composition.
- According to the present invention, there is provided an anti-inflammatory liquid composition for covering oral mucosa which is different from conventional oral care products, and with which the above-described problem can be solved.
- One aspect of the present invention is an anti-inflammatory liquid composition for covering oral mucosa including: a rosin; a shellac; and a solvent in which a content of the rosin is 1 wt% or more and 15 wt% or less relative to a total amount of the composition, and a content of the shellac is 35 wt% or more and 45 wt% or less relative to the total amount of the composition, and a total content of the rosin, the shellac, and a copal is 45 wt% or more and 55 wt% or less relative to the total amount of the composition.
- It is known that the rosin has antibacterial and anti-inflammatory effects against cariogenic bacteria and periodontopathic bacteria, as described in the documents in the related art. However, it has not been known that the wound site or inflamed site is covered with a rosin-containing film in order to protect the inflammation, wound, or the like in the oral cavity from external irritation and at the same time to maintain antibacterial and anti-inflammatory effects. As a result of studies by the present inventors, it has been demonstrated that the anti-inflammatory effect of the rosin is exhibited when the content of the rosin is more than 0.1 wt%. Therefore, in the case of using the composition according to the present invention in the oral cavity, the lower limit value of the content of the rosin is set to 1 wt% in consideration of gradual dissolution and permeation, on the assumption that the above-mentioned effect is exhibited when the content of the rosin is 10 times that of the composition.
- In addition, since the rosin is a resin ingredient obtained from pine tar, an ethanol solution of rosin has a film-forming property. However, when the film is formed with a solution of rosin alone, there is a problem that the durability of the film is short. Also, in this case, there is a problem that irritation to the mucous membrane is strong, there is a stiff feeling due to the film in the oral cavity, and there is discomfort at the time of use. Furthermore, generally, rosin is commercially available as solid gum rosin. When the rosin is used in the composition for covering oral mucosa, it is necessary that the rosin is dissolved in a solvent such as ethanol and used. Here, in order to produce an ethanol solution of rosin, the rosin is put into ethanol and dissolved under stirring. Although it is sufficient to stir the rosin solution for several minutes when the concentration of the rosin solution is several wt%, it may take several hours to stir the solution when the concentration increases. In addition, since the rosin is irritating, when the amount of rosin is increased, the affected area may be stimulated to cause pain, and therefore it is not preferable to excessively increase the concentration of the rosin. Furthermore, when the concentration of the rosin dissolved in the ethanol solvent is excessively increased, there are problems that the surface of the film formed by applying the rosin to the affected area is rough, the touch on the tongue is deteriorated, and not only discomfort is given, but also the surface of the film is cracked and easily peeled off.
- On the other hand, since the shellac as a vehicle (base material) for film formation has better performance than the rosin, it is considered that the shellac is further added in addition to the rosin, resulting in more preferable blending of the base material. Usually, shellac is commercially available as a 20 to 50% ethanol solution. Therefore, the addition of ethanol to the commercially available solution enables a shellac solution having a concentration lower than the commercially available solution to be easily obtained. In order to obtain an ethanol solution having a concentration higher than 50%, preparation can be performed by evaporating the ethanol portion in a warm bath at around 40°C or by adding dry powder shellac to the commercially available solution.
- The anti-inflammatory liquid composition for covering oral mucosa according to the present invention which has been completed based on the above findings is characterized in that the composition contains resin ingredients: a rosin and a shellac, and solvents thereof as main ingredients. Ethanol is preferably used as the solvent.
- In the anti-inflammatory liquid composition for covering oral mucosa according to the present invention, the content of the rosin as the resin ingredient described above is 1 wt% or more and 15 wt% or less, and preferably 1 wt% or more and 10 wt% or less relative to the total amount of the composition. Similarly, the content of the shellac as the resin ingredient is 35 wt% or more and 45 wt% or less, and preferably 35 wt% or more and 40 wt% or less relative to the total amount of the composition. It is essential that the total content of the rosin, the shellac, and a copal is 45 wt% or more and 55 wt% or less, and the total content is preferably 47 wt% or more and 51 wt% or less relative to the total amount of the composition. Here, the composition according to the present invention does not necessarily contain the copal, but when the composition does not contain the copal, the total content of the rosin and the shellac satisfies the above definition. When the anti-inflammatory liquid composition for covering oral mucosa according to the present invention having such characteristics is applied to a mucous membrane in the oral cavity, a solvent such as ethanol evaporates and a resin film is formed. The content of the solvent in the anti-inflammatory liquid composition for covering oral mucosa according to the present invention is 55 wt% or less, and preferably 53 wt% or less. On the other hand, the lower limit of the content of the solvent is preferably 40 wt% or more, more preferably 44 wt% or more, and particularly preferably 49 wt% or more. For example, when the solvent is ethanol, the content of ethanol in the composition is preferably 53 wt% or less. On the other hand, the lower limit of the content of ethanol is preferably 40 wt% or more, more preferably 44 wt% or more, and particularly preferably 49 wt% or more. The content of the solvent (e.g., ethanol) is preferably in a range of 49 to 53 wt%.
- Furthermore, in the anti-inflammatory liquid composition for covering oral mucosa according to the present invention, the contents of ethyl cellulose, polyvinyl acetate, and cellulose nitrate (the total content when a plurality of these materials is contained) are preferably less than 0.5 wt%. More preferably, the contents of film-forming polymeric substances including ethyl cellulose, polyvinyl acetate, and cellulose nitrate (excluding the rosin, the shellac, and the copal) are less than 0.5 wt%. This is because when the contents of the ingredients described above are 0.5 wt% or more, the quick-drying property of the film formed in the oral cavity may be deteriorated. At the time of application of the composition according to the present invention, it is necessary to keep the mouth open until the composition dries, whereby the deterioration of the quick-drying property increases the pain of the user. The content of each of the ingredients described above is preferably 0.45 wt% or less, more preferably 0.3 wt% or less, still more preferably 0.2 wt% or less, particularly preferably 0.1 wt% or less, and most preferably 0 wt% (free). The term "film-forming polymeric substance" means a polymer capable of forming a thin film on the surface of an object in a drying step.
- It is preferable that the anti-inflammatory liquid composition for covering oral mucosa according to the present invention further contains a copal as a resin ingredient. According to the composition according to the present invention, the surface of the film may be rough due to the blending of the rosin, but there is an advantage that the surface of the film formed can be made smoother by further containing the copal, and the stiffness can be reduced. The content of the copal is not particularly limited. Since the copal has a unique resin odor, when the blending amount of the copal is too large, the stiffness may be conversely increased. Thus, the content of the copal is preferably more than 0 wt% and 10 wt% or less, and more preferably 0.1 wt% or more and 8 wt% or less relative to the total amount of the composition.
- The anti-inflammatory liquid composition for covering oral mucosa according to the present invention may further contain an accessory ingredient as long as the effect of the present invention is not adversely affected. Examples of the accessory ingredient include a medicinal ingredient and a moisturizing ingredient. The contents of these accessory ingredients are preferably 1 wt% or less relative to the total amount of the composition.
- Examples of the medicinal ingredient that can be contained as an accessory ingredient include one or two or more selected from the group consisting of, for example, anti-inflammatory agents such as azulene sulfonate sodium and glycyrrhizic acid; antihistamines such as diphenhydramine hydrochloride and chlorpheniramine maleate; anti-inflammatory analgesics such as triamcinolone acetonide and dexamethasone acetate; antibiotics such as cefaclor, amoxicillin, erythromycin, and kanamycin; vitamin preparations such as vitamin B1 and vitamin E; and herbal medicines or Kampo preparations such as Angelica root, cinnamon bark, turmeric, and licorice.
- Examples of the moisturizing ingredient that can be contained as the accessory ingredient include one or two or more selected from the group consisting of glycerin, wheat germ oil, macadamia nut oil, olive oil, jojoba oil, castor oil, and a plant extract. Furthermore, a titanium-containing ingredient such as titanium oxide or titanium dioxide coated mica may be added as an accessory ingredient.
- The anti-inflammatory liquid composition for covering oral mucosa according to the present invention contains resin ingredients: a rosin and a shellac and solvents thereof as main ingredients. Thus, when the composition is applied to an inflamed area on the mucous membrane in the oral cavity using a brush or the like, a film can be formed to cover the inflamed site within about 20 seconds. Accordingly, it is possible to prevent external irritation. As a result, the pain of the affected area can be alleviated and the patient's burden can be reduced. In addition, since the rosin contained in the composition according to the present invention contains an anti-inflammatory ingredient, it is possible to prevent the expansion of the inflamed site. Furthermore, since the film of the composition according to the present invention covers and protects the affected area, healing of the inflamed site can be promoted.
- It is also found that the rosin suppresses T cell mitogen (concanavalin A)-responsive proliferation of human peripheral-blood mononuclear cells (PBMCs), and inhibits production of five cytokines (proteins secreted from cells of the immune system: IL-6, IL-10, TNF-α, IFN-γ, and IL-17) from PBMCs in a concentration-dependent manner.
- Since the composition according to the present invention contains an ingredient used as a food additive as a main ingredient, the composition is safe to be swallowed. In addition, even in the case where the film is swallowed by mistake, the film dissolves naturally and does not adhere to the mucous membrane of esophagus or the like, so there is no possibility of complication occurrence, or the like.
- It is essential that the content of the rosin as the resin ingredient described above is 1 wt% or more relative to the total amount of the composition. This is in consideration of the fact that although the antimicrobial effect of the rosin is recognized from 0.1 wt%, the rosin is gradually dissolved and permeated to exert its effect. On the other hand, the upper limit of the content of the rosin is 15 wt% or less relative to the total amount of the composition. When the content of the rosin is more than 15 wt%, the surface of the formed film becomes stiff and the touch on the tongue is deteriorated, or cracking occurs and the film is easily peeled off. This is problematic. In addition, from the viewpoint of production, in the case of preparing the composition according to the present invention by dissolving the rosin in an ethanol solution (usually, a solution having a concentration of 50%) of shellac, when the content of the rosin exceeds 15 wt%, it takes one day or more to dissolve the rosin, leading to deterioration of productivity. This is problematic.
- It is essential that the total content of the rosin and the shellac (and further a copal in the case of containing the copal) as resin ingredients is 45 wt% or more and 55 wt% or less relative to the total amount of the composition. Here, when the total content is less than 45 wt%, there is a problem that the adhesion of the formed film to the mucous membrane and the durability are deteriorated and the film is easily peeled off. In addition, as a result of the relative increase in the content of the solvent, the irritation to the mucous membrane may be enhanced. On the other hand, when the total content is more than 55 wt%, there is also a problem that the surface of the film becomes hard to cause increased stiffness, and the quick-drying property is deteriorated. When the total content is 55 wt% or less, the composition according to the present invention is dried in about 10 to 20 seconds, but this degree is the practical limit. When the total content exceeds 55 wt%, the drying time becomes long, and when the total content is, for example, 60 wt%, it takes several minutes to dry the composition. At the time of application of the composition according to the present invention, it is necessary to keep the mouth open until the composition dries, whereby the deterioration of the quick-drying property increases the pain of the user.
- As described above, it is essential that the content of the rosin in the composition according to the present invention is 1 wt% or more and 15 wt% or less relative to the total amount of the composition. The content of the shellac in the composition according to the present invention was set to a range of 35 wt% or more and 45 wt% or less relative to the total amount of the composition. As a result, the feeling of the surface of the film is made smooth, and it is possible to form a film having elasticity and high durability. Note that the film formed by applying the composition according to the present invention is practically tasteless, and even when a tongue or the like touches the film, the film cannot be easily taken off, and there is no need to refrain from drinking or eating after application.
- As described above, when the composition according to the present invention further contains a copal, the total content of the rosin, the shellac, and the copal is 45 wt% or more and 55 wt% or less. With such a configuration, the content of ethanol or the like as a solvent is 55 wt% or less, and the irritation can be reduced. Note that the film formed by the composition containing the rosin, the shellac, and the copal is not easily peeled off even when the film comes into contact with water because the film is hardly soluble in water, and there is an advantage that the film has durability for several hours even when the film is applied to a portion with significant movement in the oral cavity. In addition, when the film is applied to gums or the like with little movement, it is possible to form a film having durability for 6 hours or more.
- The composition according to the present invention not only has an effect of protecting stomatitis by coating the stomatitis to suppress inflammation, but also has an effect of suppressing proliferation of oral bacteria such as cariogenic bacteria and periodontopathic bacteria by the antibacterial activity of the rosin gradually dissolved in saliva because the film remains in the oral cavity for a long time. Alternatively, the composition is also available as a sustained oral dosage form or a new dosage form of transdermal absorption. Hence, according to another aspect of the present invention, there is also provided a pharmaceutical composition for preventing and/or treating stomatitis, including the anti-inflammatory liquid composition for covering oral mucosa according to the present invention.
- The effects of the present invention are described with reference to the following Examples and Comparative Examples. However, the technical scope of the present invention is not limited to the following Examples.
- Liquid compositions of Examples and Comparative Examples were prepared by the following method. The blending amounts of raw materials in each of the Examples and each of the Comparative Examples are shown in Table 1 below. In addition, the blending amounts of components in each of the Examples and each of the Comparative Examples are shown in Table 2 below. In principle, the Examples and Comparative Examples shown in Tables 1 and 2 are arranged in ascending order of resin concentration.
- 10.0 wt% of gum rosin (LAWTER ARGENTINA S.A.), 80.0 wt% of Laccoat 50EDS (50% shellac-ethanol solution) (manufactured by THE JAPAN SHELLAC INDUSTRIES, LTD.), 3.3 wt% of Copal HJ-01 (30% copal-ethanol solution) (manufactured by Gifu Shellac Manufacturing Co., Ltd.), and 6.7 wt% of ethanol (99.5) Imazu Class 1 (absolute ethanol) (manufactured by IMAZU CHEMICAL CO. LTD.) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 8.0 wt% of gum rosin, 80.0 wt% of Laccoat 50EDS, 6.7 wt% of Copal HJ-01, and 5.3 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 6.0 wt% of gum rosin, 80.0 wt% of Laccoat 50EDS, 13.3 wt% of Copal HJ-01, and 0.7 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 10.0 wt% of gum rosin, 80.0 wt% of Laccoat 50EDS, and 10.0 wt% of ethanol (99.5) Imazu Class 1 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 10.0 wt% of gum rosin, 70.0 wt% of Laccoat 50EDS, 16.7 wt% of Copal HJ-01, and 3.3 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 10.0 wt% of gum rosin, 76.0 wt% of Laccoat 50EDS, 3.3 wt% of Copal HJ-01, and 10.7 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 1.0 wt% of gum rosin, 80.0 wt% of Laccoat 50EDS, 15.0 wt% of a solution obtained by concentrating Copal HJ-01 to a 40% ethanol solution, and 4.0 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 3.0 wt% of gum rosin, 80.0 wt% of Laccoat 50EDS, 10.0 wt% of a solution obtained by concentrating Copal HJ-01 to a 40% ethanol solution, and 7.0 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 6.0 wt% of gum rosin, 80.0 wt% of Laccoat 50EDS, 2.5 wt% of a solution obtained by concentrating Copal HJ-01 to a 40% ethanol solution, and 11.5 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 33.3 wt% of gum rosin and 66.7 wt% of Laccoat 50EDS were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 30.0 wt% of gum rosin, 60.0 wt% of Laccoat 50EDS, and 10.0 wt% of ethanol (99.5) Imazu Class 1 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 10.0 wt% of gum rosin, 71.4 wt% of a solution obtained by concentrating Laccoat 50EDS to a 70% ethanol solution, and 18.6 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 33.3 wt% of gum rosin and 66.7 wt% of Copal HJ-01 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 25.0 wt% of gum rosin, 50.0 wt% of Laccoat 50EDS, and 25.0 wt% of ethanol (99.5) Imazu Class 1 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 10.0 wt% of gum rosin, 50.0 wt% of Laccoat 50EDS, and 40.0 wt% of Copal HJ-01 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 17.0 wt% of gum rosin, 80.0 wt% of Laccoat 50EDS, and 3.0 wt% of ethanol (99.5) Imazu Class 1 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 8.0 wt% of gum rosin, 64.0 wt% of Laccoat 50EDS, 1.7 wt% of Copal HJ-01, and 26.3 wt% of Imazu Class 1 ethanol (99.5) were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 10.0 wt% of gum rosin, 60.0 wt% of Laccoat 50EDS, and 30.0 wt% of ethanol (99.5) Imazu Class 1 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 10.0 wt% of gum rosin, 50.0 wt% of Laccoat 50EDS, and 40.0 wt% of ethanol (99.5) Imazu Class 1 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 5.0 wt% of gum rosin, 30.0 wt% of Laccoat 50EDS, and 65.0 wt% of ethanol (99.5) Imazu Class 1 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
- 50.0 wt% of gum rosin and 50.0 wt% of ethanol (99.5) Imazu Class 1 were well mixed and dissolved with a stirrer to obtain a composition in the form of uniform solution.
-
Table 1 Formulation of raw material of anti-inflammatory liquid composition for covering oral mucosa Sample Nos. Formulation ratios of raw materials (wt%) Gum rosin Laccoat *1 Copal solution *2 Ethanol *3 Total Example 1 10.0 80.0 3.3 6.7 100.0 Example 2 8.0 80.0 6.7 5.3 100.0 Example 3 6.0 80.0 13.3 0.7 100.0 Example 4 10.0 80.0 0.0 10.0 100.0 Example 5 10.0 70.0 16.7 3.3 100.0 Example 6 10.0 76.0 3.3 10.7 100.0 Example 7 1.0 80.0 15.0 *4 4.0 100.0 Example 8 3.0 80.0 10.0 *4 7.0 100.0 Example 9 6.0 80.0 2.5 *4 11.5 100.0 Comparative Example 1 33.3 66.7 0.0 0.0 100.0 Comparative Example 2 30.0 60.0 0.0 10.0 100.0 Comparative Example 3 10.0 71.4 *5 0.0 18.6 100.0 Comparative Example 4 33.3 0. 0 66.7 0.0 100.0 Comparative Example 5 25.0 50.0 0.0 25.0 100.0 Comparative Example 6 10.0 50.0 40.0 0.0 100.0 Comparative Example 7 17.0 80.0 0.0 3.0 100.0 Comparative Example 8 8.0 64.0 1.7 26.3 100.0 Comparative Example 9 10.0 60.0 0.0 30.0 100.0 Comparative Example 10 10.0 50.0 0.0 40.0 100.0 Comparative Example 11 5.0 30.0 0.0 65.0 100.0 Comparative Example 12 50.0 0.0 0.0 50.0 100.0 *1 = Laccoat 50EDS
*2 = Copal HJ-01
*3 = Ethanol (99.5) Imazu Class 1
*4 = Solution obtained by concentrating Copal HJ-01 to a 40% copal-ethanol solution
*5 = Solution obtained by concentrating Laccoat 50EDS to a 70% shellac-ethanol solution -
Table 2 Formulation of raw material of anti-inflammatory liquid composition for covering oral mucosa Sample Nos. Formulation ratios of raw materials (wt%) Rosin Shellac Copal Ethanol Total Example 1 10.0 40.0 1.0 49.0 100.0 Example 2 8.0 40.0 2.0 50.0 100.0 Example 3 6.0 40.0 4.0 50.0 100.0 Example 4 10.0 40.0 0.0 50.0 100.0 Example 5 10.0 35.0 5.0 50.0 100.0 Example 6 10.0 38.0 1.0 51.0 100.0 Example 7 1.0 40.0 6.0 53.0 100.0 Example 8 3.0 40.0 4.0 53.0 100.0 Example 9 6.0 40.0 1.0 53.0 100.0 Comparative Example 1 33.3 33.3 0.0 33.4 100.0 Comparative Example 2 30.0 30.0 0.0 40.0 100.0 Comparative Example 3 10.0 50.0 0.0 40.0 100.0 Comparative Example 4 33.3 0.0 20.0 46.7 100.0 Comparative Example 5 25.0 25.0 0.0 50.0 100.0 Comparative Example 6 10.0 25.0 12.0 53.0 100.0 Comparative Example 7 17.0 40.0 0.0 43.0 100.0 Comparative Example 8 8.0 32.0 0.5 59.5 100.0 Comparative Example 9 10.0 30.0 0.0 60.0 100.0 Comparative Example 10 10.0 25.0 0.0 65.0 100.0 Comparative Example 11 5.0 15.0 0.0 80.0 100.0 Comparative Example 12 50.0 0.0 0.0 50.0 100.0 - With respect to the liquid composition prepared in each of the above-described Examples and Comparative Examples, a sensory test using an evaluation panel of 5 subjects was performed for the irritation to the mucous membrane in the oral cavity of the human body, the feeling of the applied film, and the quick-drying property and durability of the applied film.
- For 5 subjects, the degree of irritation at the time of applying the liquid composition after wiping off saliva at the inner edge of the lower lip, i.e., a mucous membrane in the oral cavity, was evaluated according to the following three grades: 0 to 2, and the results of 5 subjects were averaged. When the average value was less than 1.5, it was determined that there was no practical problem. The results are shown in Table 3 below:
Irritation: - Almost no irritation is felt = 0
- Slight irritation is felt = 1
- Irritation is felt = 2.
- The liquid composition was applied to 5 subjects after wiping off saliva at the inner edge of the lower lip, i.e., a mucous membrane in the oral cavity, followed by drying until a film was formed. Thereafter, the feeling at the lower portion of the surface of the film or the feeling in the oral cavity, i.e., tensive feeling or stiff feeling on the surface of the film, was evaluated according to the following three grades: 0 to 2, and the results of 5 subjects were averaged. When the average value was less than 1.5, it was determined that there was no practical problem. The results are shown in Table 3 below:
Stiffness: - No stiffness is felt = 0
- Slight stiffness is felt = 1
- Stiffness is concerned = 2.
- The liquid composition was applied to 5 subjects after wiping off saliva at the inner edge of the lower lip, i.e., a mucous membrane in the oral cavity. After 10 seconds, the degree of dryness of the film was checked with a fingertip. After 20 seconds, the degree of dryness was checked again with a fingertip and evaluated according to the following three grades: 0 to 2, and the results of 5 people were averaged. When the average value was less than 1.5, it was determined that there was no practical problem. The results are shown in Table 3 below:
Quick-drying property: - The sticky feeling of the fingertip is lost within 10 seconds = 0
- The sticky feeling of the fingertip is lost within 20 seconds = 1
- Even after 20 seconds, the sticky feeling of the fingertip is not lost = 2.
- The liquid composition was applied to the inner edge of the lower lip and the outside of the upper gum of each of the 5 subjects. Next, it was confirmed whether or not the covering material remained every hour. At this time, checking was carried out in 1 hour, the subjects drank water or gargled lightly. In addition, checking was carried out in 2 hours, and then the subjects had meals. Furthermore, checking was carried out in 3 hours, and then the subjects were allowed to freely drink water and have meals.
- Then, the time when the whole covering material was peeled off was recorded. At this time, for example, when the film was peeled off at the time of checking 1 hour later, it was recorded as 1 hour, when the film was remained at the time of checking 2 hours later, but peeled off at the time of checking 3 hours later, it was recorded as 3 hours, when the film was peeled off at the time of checking 7 hours later, it was recorded as 7 hours, and when the film was not peeled at that time, it was uniformly recorded as 8 hours. After completion of the recording, the results of 5 subjects were averaged. Then, for the inner edge of the lower lip, it was determined that there was no practical problem if the average value was 2.0 hours or more. For the outside of the upper gum, it was determined that there was no practical problem if the average value was 5.0 hours or more. The results are shown in Table 3 below. The results that do not satisfy the unacceptable evaluation criteria shown in Table 3 are indicated by "▲".
[Table 3] Sample Nos. Sensory test Irritation Feeling Quick-drying property Durability The inner edge of the lower lip The outside of the upper gum Example 1 0.2 0.0 0. 8 4.2 7.6 Example 2 0.6 0.4 0.6 3.0 8.0 Example 3 1.0 0.2 1.0 2.6 7.2 Example 4 0.2 0.6 0. 8 4.0 7.4 Example 5 0.6 0.6 1.4 2.2 7.0 Example 6 0.6 0.4 0.6 3.4 8.0 Example 7 0.6 0.2 1.2 3.0 5.4 Example 8 0.8 0.0 1.2 3.4 5.8 Example 9 0.6 0.4 0. 8 3.0 5.6 Comparative Example 1 0.8 0.4 2.0 ▲ 2.2 7.0 Comparative Example 2 0.2 1.0 1.6 A 2.6 7.0 Comparative Example 3 0.0 0.0 2.0 ▲ 3.2 8.0 Comparative Example 4 0.8 1.6 A 1.6 ▲ 1.4 ▲ 4.2 ▲ Comparative Example 5 1.0 1.2 1.8 ▲ 3.0 8.0 Comparative Example 6 0.6 0.6 1.6 ▲ 4.0 7.4 Comparative Example 7 0.6 0.8 1.6 ▲ 2.2 8.0 Comparative Example 8 0.8 0.2 1.6 ▲ 3.2 8.8 Comparative Example 9 1.4 0.4 0. 8 2.6 3.6 A Comparative Example 10 1.6 A 0.6 1.0 4.0 6.2 Comparative Example 11 1.8 A 0.0 0.2 1.8 A 3.4 ▲ Comparative Example 12 0.8 1.6 ▲ 1.4 1.8 A 4.8 A Unacceptable evaluation criteria 1.5 ↑ 1.5 ↑ 1.5 ↑ 2.0 ↓ 5.0 ↓ - From the results shown in Table 3, it is found that the irritation tends to deteriorate as the concentration of the solvent increases. For example, this tendency was remarkably shown in Comparative Examples 8 to 11. On the other hand, when the concentration of the solvent was too low and the concentration of the resin was too high, the quick-drying property tended to deteriorate (for example, Comparative Examples 1 to 3).
- The feeling of the film surface tended to deteriorate as the rosin concentration increased. This tendency was observed in Comparative Examples 4, 5, and 12, and the like.
- The addition of the copal improved the feeling of the film surface. This is apparent from the comparison between Example 4 and Comparative Example 11, for example.
- The addition of the shellac improved the feeling, quick-drying property, and durability of the film. This is apparent from the fact that Comparative Examples 4 and 12 without addition of the shellac were inferior in all respects of feeling, quick-drying property, and durability.
- This application is based on
Japanese Patent Application No. 2019-229561 filed on December 19, 2019
Claims (9)
- An anti-inflammatory liquid composition for covering oral mucosa comprising:a rosin;a shellac; anda solvent;wherein a content of the rosin is 1 wt% or more and 15 wt% or less relative to a total amount of the composition, anda content of the shellac is 35 wt% or more and 45 wt% or less relative to the total amount of the composition, anda total content of the rosin, the shellac, and a copal is 45 wt% or more and 55 wt% or less relative to the total amount of the composition.
- The anti-inflammatory liquid composition for covering oral mucosa according to claim 1, further comprising a copal.
- The anti-inflammatory liquid composition for covering oral mucosa according to claim 2, wherein a content of the copal is more than 0 wt% and 10 wt% or less relative to a total amount of the composition.
- The anti-inflammatory liquid composition for covering oral mucosa according to any one of claims 1 to 3, wherein the solvent contains ethanol.
- The anti-inflammatory liquid composition for covering oral mucosa according to any one of claims 1 to 4, further comprising an accessory ingredient containing a medicinal ingredient and/or a moisturizing ingredient.
- The anti-inflammatory liquid composition for covering oral mucosa according to claim 5, wherein a content of the accessory ingredient is 1 wt% or less relative to a total amount of the composition.
- The anti-inflammatory liquid composition for covering oral mucosa according to claim 5 or 6, wherein the medicinal ingredient contains one or two or more selected from the group consisting of an anti-inflammatory agent, an antihistamine, an anti-inflammatory analgesic, an antibiotic, a vitamin preparation, a herbal medicine, and a Kampo preparation.
- The anti-inflammatory liquid composition for covering oral mucosa according to any one of claims 5 to 7, wherein the moisturizing ingredient contains one or two or more selected from the group consisting of glycerin, wheat germ oil, macadamia nut oil, olive oil, jojoba oil, castor oil, and a plant extract.
- A pharmaceutical composition for preventing and/or treating stomatitis, comprising the anti-inflammatory liquid composition for covering oral mucosa according to any one of claims 1 to 8.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019229561A JP6806388B1 (en) | 2019-12-19 | 2019-12-19 | An anti-inflammatory liquid composition for covering the oral mucosa, and a pharmaceutical composition for preventing and / or treating aphthous ulcer using the same. |
PCT/JP2020/047388 WO2021125315A1 (en) | 2019-12-19 | 2020-12-18 | Anti-inflammatory liquid composition for covering oral mucosa, and medicinal composition for prevention and/or treatment of stomatitis using same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4079281A1 true EP4079281A1 (en) | 2022-10-26 |
EP4079281A4 EP4079281A4 (en) | 2023-01-25 |
Family
ID=73993008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20902159.1A Pending EP4079281A4 (en) | 2019-12-19 | 2020-12-18 | Anti-inflammatory liquid composition for covering oral mucosa, and medicinal composition for prevention and/or treatment of stomatitis using same |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230017654A1 (en) |
EP (1) | EP4079281A4 (en) |
JP (1) | JP6806388B1 (en) |
CN (1) | CN114746082B (en) |
TW (1) | TW202135847A (en) |
WO (1) | WO2021125315A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7109827B1 (en) | 2021-11-16 | 2022-08-01 | 株式会社ハニック・ホワイトラボ | antiviral agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0637386B2 (en) * | 1985-12-13 | 1994-05-18 | ライオン株式会社 | Retention type base for oral cavity |
JPH0466523A (en) | 1990-07-04 | 1992-03-02 | Kanebo Ltd | Agent for suppressing proliferation of pathogen of periodontosis |
WO2005020937A1 (en) * | 2003-08-27 | 2005-03-10 | Hanix Co., Ltd. | Composition for application to tooth |
US20050175552A1 (en) * | 2004-02-10 | 2005-08-11 | Hoic Diego A. | Tooth coating compositions and methods therefor |
GB0514943D0 (en) | 2005-07-20 | 2005-08-24 | Botan Ltd | Oral care compositions |
US20090142282A1 (en) * | 2007-12-04 | 2009-06-04 | Jonathan Lee Kendall | High-solids alcoholic solutions of rosin esters for varnish applications |
RU2367407C1 (en) * | 2007-12-21 | 2009-09-20 | Закрытое акционерное общество "Опытно-экспериментальный завод "ВладМиВа" | Dental varnish |
AR071183A1 (en) * | 2008-04-04 | 2010-06-02 | Colgate Palmolive Co | ORAL COMPOSITION THAT INCLUDES AN ACTIVE COMPONENT AND AN ADHESIVE FILM FORMING COMPONENT, METHOD |
JP2011162470A (en) * | 2010-02-09 | 2011-08-25 | Gc Corp | Tooth coating material |
KR101759525B1 (en) * | 2016-12-01 | 2017-07-31 | (주)메디케이 | Tooth coating products and compositions thereof |
-
2019
- 2019-12-19 JP JP2019229561A patent/JP6806388B1/en active Active
-
2020
- 2020-12-17 TW TW109144809A patent/TW202135847A/en unknown
- 2020-12-18 EP EP20902159.1A patent/EP4079281A4/en active Pending
- 2020-12-18 CN CN202080082826.0A patent/CN114746082B/en active Active
- 2020-12-18 US US17/783,547 patent/US20230017654A1/en active Pending
- 2020-12-18 WO PCT/JP2020/047388 patent/WO2021125315A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021095381A (en) | 2021-06-24 |
CN114746082A (en) | 2022-07-12 |
JP6806388B1 (en) | 2021-01-06 |
TW202135847A (en) | 2021-10-01 |
US20230017654A1 (en) | 2023-01-19 |
EP4079281A4 (en) | 2023-01-25 |
WO2021125315A1 (en) | 2021-06-24 |
CN114746082B (en) | 2024-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4307075A (en) | Topical treatment of aphthous stomatitis | |
US9161909B2 (en) | Adhesive compositions for the treatment of xerostomia | |
US8182843B2 (en) | Herbal compositions for the treatment of diseases of the oral cavity | |
CN106729656B (en) | Oral care composition for treating dry mouth and application of oral care composition in toothpaste | |
US10843013B2 (en) | Liquid precursor compositions and uses thereof for a ph-dependant sustained release treatment of oral disorders | |
WO2009106963A2 (en) | Dental composition for preventing and treating stomatitis and mouth ulcers | |
KR20070006294A (en) | Phase transitive breath care products | |
EP2545899B1 (en) | Composition for the prophylaxis of candidiasis | |
JPH059412B2 (en) | ||
US20090053309A1 (en) | Adhesive compositions for the treatment of xerostomia | |
Burgess et al. | Review of over-the-counter treatments for aphthous ulceration and results from use of a dissolving oral patch containing glycyrrhiza complex herbal extract | |
US5503822A (en) | Medicated gel | |
EP4079281A1 (en) | Anti-inflammatory liquid composition for covering oral mucosa, and medicinal composition for prevention and/or treatment of stomatitis using same | |
US10813878B2 (en) | Oral health composition | |
EP3656370A1 (en) | Pharmaceutical composition and its use for the prevention and treatment of oral cavity pathologies | |
US20220023426A1 (en) | Oral mucosal carrier and protectant | |
KR102569590B1 (en) | Film type dentifrice | |
US5409691A (en) | Solution comprising aluminum acetate and glycerin | |
JP5455203B2 (en) | Film preparation and method for producing the same | |
JP6752101B2 (en) | Composition for oral mucosa containing triamcinolone acetonide | |
AU2007264709B2 (en) | Herbal compositions for the treatment of diseases of the oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220609 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230102 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C08L 93/04 20060101ALI20221220BHEP Ipc: A61K 6/20 20200101ALI20221220BHEP Ipc: C08L 93/02 20060101ALI20221220BHEP Ipc: A61K 36/32 20060101ALI20221220BHEP Ipc: A61K 35/00 20060101ALI20221220BHEP Ipc: A61K 8/92 20060101ALI20221220BHEP Ipc: A61P 31/04 20060101ALI20221220BHEP Ipc: A61P 29/00 20060101ALI20221220BHEP Ipc: A61P 1/02 20060101ALI20221220BHEP Ipc: A61K 47/44 20170101ALI20221220BHEP Ipc: A61K 47/10 20170101ALI20221220BHEP Ipc: A61K 36/15 20060101ALI20221220BHEP Ipc: A61K 9/08 20060101ALI20221220BHEP Ipc: A61K 6/884 20200101AFI20221220BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231127 |